NDA221291 ()

Where it stands

The records show US application NDA221291, sponsored by Bayer Healthcare, as Approved. The FDA approval milestone is dated 2026-11-09 and is marked as an official source. The entry describes it as the approval of "a new medicine".

The records do not give a product name, active substance, therapeutic area or indication. The scope of the approval, meaning the patient population, dose and conditions of use, therefore cannot be assessed from this data. Any commentary on clinical positioning would be speculation.

Regulatory pathway and designations

The product is recorded as a New Molecular Entity (NME) reviewed under a New Drug Application (NDA). In general, an NME is an active moiety the FDA has not previously approved in the US, either alone or in combination. Such products are typically reviewed by the FDA's Center for Drug Evaluation and Research.

It also carries a Priority review designation. In general, this is granted to applications for drugs that the FDA judges could offer a significant improvement in the treatment, diagnosis or prevention of a serious condition. Under PDUFA, it carries a shortened review goal of six months from the 60-day filing date, versus ten months for standard review.

The records do not say which scientific or clinical grounds supported the priority designation. They also do not say whether other programs applied, such as Breakthrough Therapy, Fast Track or Accelerated Approval, or whether an advisory committee was held. The submission date and PDUFA goal date are not provided either, so review timing cannot be measured.

Safety and pharmacovigilance

The records contain no information on the safety profile, boxed warnings, contraindications, REMS, postmarketing requirements or pharmacovigilance commitments for this product.

What to watch

The first step is to obtain the approval letter, the prescribing information and the FDA review documents, usually available through Drugs@FDA. These would establish the product identity, the approved indication, the dosing and any labeled safety language. They would also show whether the FDA imposed postmarketing requirements or commitments.

The records show no CHMP opinion date and no EU regulatory activity. Whether and when Bayer pursues or has pursued an EMA submission cannot be determined from this data. Readers tracking EU availability should check the EMA's published information separately.

Commercial launch timing, labeling updates and any early postmarketing safety communications are not covered by the records. Each would need to be confirmed from primary sources.